Trials / Completed
CompletedNCT02431754
A Study of Tadalafil (LY450190) in Participants With Lower Urinary Tract Symptoms (LUTS) Suggestive of Benign Prostatic Hyperplasia LUTS (BPH-LUTS).
A Post-Marketing Clinical Study of LY450190 (Combined With Alpha1 Blocker Treatment)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 171 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- Male
- Age
- 45 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the safety and efficacy of the study drug known as tadalafil in participants with benign prostatic hyperplasia who are being treated with an alpha1 blocker. This study has two treatment periods. Participants will receive tadalafil or placebo in each treatment period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tadalafil | Administered orally |
| DRUG | Placebo | Administered orally |
| DRUG | Alpha1 Blocker | Administered orally |
Timeline
- Start date
- 2015-04-01
- Primary completion
- 2016-02-01
- Completion
- 2016-02-01
- First posted
- 2015-05-01
- Last updated
- 2017-07-02
- Results posted
- 2017-03-01
Locations
9 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT02431754. Inclusion in this directory is not an endorsement.